Results 141 to 150 of about 191,208 (362)

Expression and immmunogenicity of HLA-B27 in high-transfection recipient P815: [PDF]

open access: yes, 1989
Kuon, W.   +4 more
core   +1 more source

Association of HLA-B27 antigen with clinical and laboratory parameters in patients with juvenile idiopathic arthritis

open access: gold, 2022
Adisa Čengić   +5 more
openalex   +1 more source

The possible Association of HLA Class II with Bladder Cancer in Iraqi Patients

open access: yesمجلة كلية الطب, 2008
Background: - Genetic Factors have a major role in the development of bladder cancer. Objectives: - This study was carried out to shed a light on the possible association of HLA class II antigens and BC patients and to correlate this finding with the ...
Shatha M.J. Al-Khateeb   +4 more
doaj  

Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy. [PDF]

open access: yes, 2018
Malignant gliomas carry a dismal prognosis. Conventional treatment using chemo- and radiotherapy has limited efficacy with adverse events. Therapy with genetically engineered T-cells, such as chimeric antigen receptor (CAR) T-cells, may represent a ...
Almeida, Neil D   +4 more
core  

Resistance potential of the HLA-A2-restricted immunodominant SARS-CoV-2-specific CD8+ T cell receptor repertoire to antigenic drift [PDF]

open access: gold
Michael J. Malone   +7 more
openalex   +1 more source

Single‐Cell Level Characterization of B Cell Depletion and Repopulation Following Rituximab in Systemic Lupus Erythematosus

open access: yesArthritis &Rheumatology, EarlyView.
Objective Rituximab, a CD20+ B cell depletion therapy, is frequently used to treat systemic lupus erythematosus (SLE). However, variability in patient response highlights the need for a deeper understanding of the underlying immune cell dynamics of B cell depletion and repopulation.
Haerin Jang   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy